Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced positive preclinical data supporting the activity of SBP-101 in ovarian cancer cell lines.
Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1b Trial Investigating SBP-101 Combination Therapy for First-Line Metastatic Pancreatic Cancer
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA).
Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective December 2, 2020.
Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, announced receipt... Read More
Sun BioPharma Provides Business Update and Reports Operating Results for FY2019
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic cancer, provided a business update... Read More
Sun BioPharma, Inc. Presents SBP-101 Phase 1 Clinical Data
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, summarized initial... Read More
Sun BioPharma, Inc. Provides an Update on Ongoing Front-Line Pancreatic Cancer Clinical Trial
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, provides an update on... Read More
Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach (Globe Newswire)
UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases, announced that it will present... Read More
Sun BioPharma Announces Leadership Changes (Globe Newswire)
UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, announced leadership changes... Read More
Lion’s Club Hears From Sun BioPharma Founder on Cancer Treatments (IslandReporter)
The featured speaker at the Sanibel-Captiva Lions Club’s dinner meeting, held on Aug. 15 in the Founders Room at The Community House,... Read More
